Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
The acetylcholine esterase inhibitor/cholinergic nicotinic receptor (nAChR) allosteric modulator galantamine (Gal) is used against cognitive impairment in Alzheimer's disease. Negative/cognitive and psychotic symptom improvement in schizophrenia by adjunct Gal to antipsychotic drugs (APDs) has been reported. Cognitive symptoms in schizophrenia may involve brain prefrontal hypo-dopaminergia. Experimental data by others indicate nAChR involvement in animal pro-cognitive effects of Gal. The role of nAChRs in antipsychotic effects by Gal has, however, not been elucidated. Using the conditioned avoidance response (CAR) and the catalepsy tests for antipsychotic activity and extrapyramidal side-effect (EPS) liability, respectively, we here investigated the effects of adjunct Gal (1.25 mg/kg) to the typical APD haloperidol (Hal) (0.05 mg/kg), or the atypical APD risperidone (Ris) (0.2 mg/kg), in rats. Adjunct Gal significantly enhanced APD-like effects by low doses of Hal or Ris, but showed a safe EPS liability profile only in combination with Ris. Pretreatment with the muscarinic receptor (mAChR) antagonist scopolamine, but not the nAChR antagonist mecamylamine, completely reversed the enhancing effects of adjunct Gal to Hal treatment, in the CAR test. While the nAChR-modulating properties of Gal probably contribute to pro-cognitive activity, as shown by others, the present data suggest that any contribution to antipsychotic activity by Gal is mediated primarily via mAChRs. This property combination of Gal may offer a unique, favourable therapeutic profile for schizophrenia treatment.
Wadenberg
Marie-Louise G
ML
Linnaeus University, School of Natural Sciences, Kalmar, Sweden. marie-louise.wadenberg@lnu.se
Fjällström
Ann-Kristin
AK
Federley
Malin
M
Persson
Pernilla
P
Stenqvist
Pia
P
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D002375:Catalepsy / Q000188:drug therapy; D018680:Cholinergic Antagonists / Q000494:pharmacology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005116:Extrapyramidal Tracts / Q000187:drug effects; D005702:Galantamine / Q000627:therapeutic use*; D006220:Haloperidol / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D018733:Nicotinic Antagonists / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011976:Receptors, Muscarinic / Q000502:physiology*; D018967:Risperidone / Q000627:therapeutic use* / Q000633:toxicity; D012559:Schizophrenia / Q000188:drug therapy*; D012601:Scopolamine / Q000494:pharmacology
D014150:Antipsychotic Agents; D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D018733:Nicotinic Antagonists; D011976:Receptors, Muscarinic; D005702:Galantamine; D008464:Mecamylamine; D012601:Scopolamine; D006220:Haloperidol; D018967:Risperidone